Inflammation/Bone Metabolism Division Wyeth-Ayerst Research CN 8000 Princeton NJ 08543-8000 USA.
Mediators Inflamm. 1992;1(6):411-7. doi: 10.1155/S0962935192000620.
The effect of selective PDE-I (vinpocetine), PDE-III (milrinone, CI-930), PDE-IV (rolipram, nitroquazone), and PDE-V (zaprinast) isozyme inhibitors on TNF-alpha and IL-1beta production from LPS stimulated human monocytes was investigated. The PDE-IV inhibitors caused a concentration dependent inhibition of TNF-alpha production, but only partially inhibited IL-1beta at high concentrations. High concentrations of the PDE-III inhibitors weakly inhibited TNF-alpha, but had no effect on IL-1beta production. PDE-V inhibition was associated with an augmentation of cytokine secretion. Studies with combinations of PDE isozyme inhibitors indicated that PDE-III and PDE-V inhibitors modulate rolipram's suppression of TNF production in an additive manner. These data confirm that TNF-alpha and IL-1beta production from LPS stimulated human monocytes are differentially regulated, and suggest that PDE-IV inhibitors have the potential to suppress TNF levels in man.
研究了选择性 PDE-I(长春西汀)、PDE-III(米力农、CI-930)、PDE-IV(罗利普兰、硝喹酮)和 PDE-V(扎普司特)同工酶抑制剂对 LPS 刺激的人单核细胞产生 TNF-α和 IL-1β的影响。PDE-IV 抑制剂呈浓度依赖性抑制 TNF-α产生,但在高浓度时仅部分抑制 IL-1β。高浓度 PDE-III 抑制剂对 TNF-α抑制作用较弱,但对 IL-1β产生无影响。PDE-V 抑制与细胞因子分泌增加有关。PDE 同工酶抑制剂组合研究表明,PDE-III 和 PDE-V 抑制剂以相加的方式调节罗利普兰对 TNF 产生的抑制作用。这些数据证实了 LPS 刺激的人单核细胞产生的 TNF-α和 IL-1β受到不同的调节,并表明 PDE-IV 抑制剂有可能抑制人体内的 TNF 水平。